• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Seattle Genetics - Articles and news items

Takeda & Seattle Genetics announce positive data from trial for cutaneous T-cell lymphoma 

Takeda and Seattle Genetics announce positive data from trial for cutaneous T-cell lymphoma 

Industry news / 1 August 2016 / Takeda Pharmaceutical Company Ltd and Seattle Genetics, Inc.

Takeda and Seattle Genetics announce that the ALCANZA trial evaluating ADCETRIS for cutaneous T-cell lymphoma demonstrated significant improvement…

adcetris

Five-year data from Phase II trial of Adcetris published

Industry news / 19 July 2016 / Victoria White, Digital Content Producer

The data comes from a Phase II trial of Adcetris (brentuximab vedotin) in patients with relapsed or refractory classical Hodgkin lymphoma…

Adcetris

Trial of Adcetris and Opdivo in non-Hodgkin lymophoma starts

Industry news / 23 December 2015 / Victoria White

The phase 1/2 clinical trial will evaluate Adcetris (brentuximab vedotin) in combination with Opdivo (nivolumab) in patients with CD30-expressing relapsed or refractory B-cell and T-cell non-Hodgkin lymphomas…

Adcetris

Phase 3 trial of Adcetris in Hodgkin lymphoma completes target enrolment

Industry news / 27 October 2015 / Victoria White

Data from a Phase 1 trial evaluating Adcetris plus AVD demonstrated that 24 of 25 patients (96 percent) achieved a complete remission…

 

Webinar: Different thermal analysis techniques to measure the glass transitionWATCH NOW
+ +